(Philadelphia, PA) – Seventy-six (76) Temple physicians have been named to Philadelphia magazine’s “Top Doctors” list for 2017. Thirty-seven are Fox Chase Cancer Center physicians.
PHILADELPHIA (April 13, 2017) – Genetics experts from Fox Chase Cancer Center are calling for more caution around how doctors assess genetic testing information for patients’ genetic predisposition to breast cancer risk.
PHILADELPHIA (April 10, 2017) — A new clinical study is available for prostate cancer patients who are concerned about recurrence. The study is using a new imaging agent to reveal how tissue and organs are functioning. In the study, researchers are examining whether this more targeted imaging can lead to changed or better treatment plans for patients.
Philadelphia (April 3, 2017) – Throughout April, Fox Chase Cancer Center aims to educate individuals about head and neck cancers, including risk factors, signs, and symptoms. Head and neck cancer includes a number of different malignant tumors that develop in or around the throat, larynx (voice box), nose, sinuses and mouth.
PHILADELPHIA (April 3, 2017) – Researchers at Fox Chase Cancer Center have begun to establish a biological basis for the long-held, but not well-tested theory that neighborhood exposures can impact health outcomes. They found that a biomarker implicated in cancer, telomere length (TL), could be influenced by sociodemographic circumstances associated with neighborhood.
PHILADELPHIA (March 27, 2017) – Researchers from Fox Chase Cancer Center have created a new computational approach to determine whether neighborhood circumstances can influence the aggressiveness of prostate cancer. Although it will need to be tested in other studies, the development of a method that is common to both genetics and the neighborhood or social environment in which people live could have relevance to the Precision Medicine Initiative.
PHILADELPHIA (March 16, 2017) — Philip H. Abbosh, MD, PhD, assistant research professor at Fox Chase, led a research team searching for evidence that chemotherapy may activate the immune system to eradicate bladder cancer. A poster of the study is being presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC on Tuesday, April 4.